Palnat 125 Capsules — Palbociclib 125 mg (21 Caps) Natco
Palnat 125 mg (Palbociclib) is an advanced targeted oncology medication belonging to the class of selective cyclin-dependent kinase (CDK 4/6) inhibitors. It works by interfering with the process that allows cancer cells to divide and multiply. By arresting the cell cycle, Palnat effectively slows the progression of hormone-sensitive tumors and stabilizes the disease.
Manufacturer: Natco Pharma Ltd. (India). 🇮🇳 Manufactured by one of India's premier pharmaceutical companies under strict GMP compliance. This medication provides full therapeutic equivalence to the original palbociclib molecule, ensuring consistent potency, high purification levels, and proven bioavailability for patient safety.
Key Features:
- ✅ Precision Proliferation Control: Selectively inhibits the specific enzymes that drive the rapid growth of malignant cells.
- ✅ Restores Biological Balance: Re-activates the cellular pathways that prevent uncontrolled tumor expansion.
- ✅ Cycle-Specific Design: The 21-capsule presentation is perfectly aligned with the standard active dosing phase of the treatment protocol.
Prescribed by an oncologist for the treatment of women with:
- 🔹 Breast Cancer: Hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer.
- 🔹 Combination Therapy: Used in combination with an aromatase inhibitor (e.g., letrozole) as initial endocrine-based therapy or with fulvestrant in women whose disease has progressed following prior hormone therapy.
Sales Unit: Bottle in a carton box containing 21 capsules. Strength: 125 mg per capsule.
⚠️ APPLICATION INSTRUCTIONS:
- Cycle Schedule: The standard dose is 125 mg (1 capsule) once daily for 21 consecutive days, followed by a 7-day rest period (a complete 28-day cycle).
- Administration: Palnat capsules must be taken with food. This is essential for proper absorption of the medication into the bloodstream. Swallow the capsule whole; do not open, crush, or chew it.
- ✋ Dietary Warning: Strictly avoid grapefruit and grapefruit juice during treatment, as they can interfere with drug metabolism and lead to toxicity.
- ⛔ Drug Interactions: Do not use concurrently with strong CYP3A inhibitors or inducers (e.g., certain antibiotics, antifungals, or anticonvulsants).
- Hypersensitivity to palbociclib or any ingredients.
- Pregnancy and breastfeeding (highly teratogenic). Women of childbearing potential must use effective contraception during and after treatment.
- Children and adolescents under 18 years of age.
Treatment requires regular medical supervision and frequent blood tests. Potential side effects include:
- 🩸 Blood Counts: Neutropenia (very common, requires routine white blood cell monitoring), anemia, thrombocytopenia.
- 🦠 Immunity: Increased susceptibility to respiratory tract infections.
- 💤 General: Fatigue, asthenia, decreased appetite.
- 🤢 Gastrointestinal: Stomatitis (mouth sores), nausea, diarrhea.
- 💇♀️ Hair: Hair thinning or loss (alopecia).
Similar products
What Customers Say
No reviews yet
Your review can be the first!